Sustainability and corporate social responsibility
In this issue, our cover article by Danny Buckland focuses on pharma’s vital role in sustainability and corporate social responsibility. As global companies outlined decarbonisation plans across active pharmaceutical ingredient supply chains at COP27, the Lancet Countdown 2022 Report stated: ‘The world faces a critical juncture. A health-centred, aligned response to the compounding crises can still deliver a future where people can not only survive, but thrive.’
As Danny says: ‘It is now clear that devising corporate social responsibility programmes aligned solely to an organisation’s therapy areas or narrow corporate responsibilities will not be enough.
‘If the pharma industry was a country, it would be the fifth largest emitter of carbon on the earth, and it is facing the glare of scrutiny lasering into every process and action that could influence its impact on the health of society – and the health of the planet.
‘How organisations tackle these challenges – alongside the day job of discovering, developing, manufacturing and getting therapies to patients – is having an increasing effect on their ability to function, connect with HCPs, identify with patients, attract investors and build a brand reputation with the wider public. It is a mountainous task even for an industry that thrives on facing and overcoming the intractable.’ Read more on page 32.
Also in this month’s issue, Paul Chew, Chief Medical Office at Phesi, talks about addressing the diversity issue in clinical trials and how patient-centric analytics can be used to design more diverse, inclusive and equitable trials. Turn to page 18 to find out more.
Looking ahead, our January issue will focus on innovation in digital healthcare and how remote monitoring is improving patient outcomes.
If you would like to make your voice heard on these topics, please get in touch at sales@pmlive.com
I hope you enjoy this issue!
